Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®​): 6-months, open label, observational, non-interventional study - Degering, J; Egenlauf, B; Harutyunova, S; Benjamin, N; Xanthouli, P; Salkic, A; Eichstaedt, C; Seeger, R; Grünig, E (Pneumologie, 2023)